WDR48 and cancer: In the future it would be very interesting to screen different human cancers for additional WDR48 mutations that might not only be defective in maintaining PHLPP1 function but also other substrates such as BRCA1, FANCD2, H2A/H2B, PCNA, and notch receptor.